AstraZeneca: licensing agreement with RQ Biotechnology
(CercleFinance.com) - AstraZeneca announces that it has entered into a licensing agreement with RQ Biotechnology for a portfolio of early stage monoclonal antibodies (mAbs) targeting SARS-CoV-2, the virus that causes Covid-19.
As part of the agreement, AstraZeneca has acquired an exclusive worldwide licence to develop, manufacture and market mAbs against SARS-CoV-2.
RQ Bio is a British biotechnology company that develops treatments and preventive therapies based on potent broad-spectrum mAbs to address unmet needs in vulnerable patient populations.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
As part of the agreement, AstraZeneca has acquired an exclusive worldwide licence to develop, manufacture and market mAbs against SARS-CoV-2.
RQ Bio is a British biotechnology company that develops treatments and preventive therapies based on potent broad-spectrum mAbs to address unmet needs in vulnerable patient populations.
Copyright (c) 2022 CercleFinance.com. All rights reserved.